Aurinia Settles Patent Fight With Teva Over Generic Voclosporin
AUPH sits 60% above its 52-week low of $10.34.
Summary
Aurinia resolved patent infringement litigation with Teva over Teva's abbreviated NDA for generic 7.9 mg voclosporin capsules. The settlement removes a key overhang on LUPKYNIS exclusivity, though terms are undisclosed. Teva may launch its generic voclosporin product no earlier than December 7, 2036, unless certain defined contingencies occur earlier. Teva stipulated that Aurinia's patents are enforceable, valid, and would be infringed. Related patent infringement actions continue against DifGen Pharmaceuticals, Dr. Reddy's, and others. This follows strong Q2 results showing LUPKYNIS sales up 19% to $79.4M.
At the time of this announcement, AUPH was trading at $16.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $10.34 to $19.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.